Award will fund new scale-up innovations to help make Oxitec’s Friendly™ Aedes aegypti technology accessible to low-income communities worldwide suffering from dengue, Zika, and chikungunya.

Building on the successful performance of the technology in Brazil over the last three years, this award will fund Oxitec’s work on new production scale-up innovations, product features and methodologies that are focused on reducing costs and improving accessibility of the technology for those communities suffering most from Aedes aegypti-transmitted diseases.

Grey Frandsen, Oxitec’s CEO, said, “We are immensely grateful for Wellcome’s partnership and support as we work to make our Friendly™ Aedes aegypti solution universally accessible to communities most in need around the world. We are pleased that the Wellcome Trust believes in this vision and shares in our aim to scale this technology as quickly as possible so we can deliver real impact in the global fight against dengue and other vector-borne diseases.”

Oxitec Press Inquiries: press@oxitec.com

Oxitec is the leading developer of insect-based biological solutions to control pests that transmit disease, destroy crops and harm livestock. Founded in 2002 at the University of Oxford, Oxitec is led by a passionate team comprised of 15 nationalities and is supported by world-class partners. Learn more at oxitec.com.

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, global heating and infectious diseases.

Supported by the Wellcome Trust, grant number 221376/Z/20/20.Source: https://www.oxitec.com/en/news/oxitec-receives-us68-million-from-wellcome-trust-to-advance-scale-up-of-friendly-aedes-aegypti-technology